Malignant gliomas are the most common primary brain tumors in adults up to an extent of 78% of all primary malignant brain tumors. The efficacy of current multimodal therapeutic strategies in gliomas is limited by the lack of specific therapies against malignant cells, and the prognosis in patients affected by primary brain tumors is still very unfavorable. Late diagnosis and the limitation of conventional therapies, which may result from inefficient delivery of the therapeutic or contrast agent to brain tumors are major reasons for this unsolved clinical problem. The difficult in overcoming the blood-brain barrier is the biggest obstacle for chemotherapeutics, which cannot reach the tumor bed as efficacious doses. The advent of nanotechnology could revolutionized the approach to that. Nanotechnology in biomedical research has quickly found its own niche in clinical methodologies including imaging, diagnostic, and therapeutics. Nanoparticles are versatile, thanks to their particular chemical configuration, and are able to go through the blood-brain barrier carrying drugs or genes targeted against brain tumors. Nanoparticle systems provide prolonged drug delivery directly to the tumor following direct intracerebral injection or by functionalizing the material surface with peptides and ligands allowing the drug-loaded material to be specifically target the tumor cells. In this chapter we describe the principal applications of nanomedicine in brain tumor treatment. Finally, we will report various preclinical and/or clinical studies in brain tumor treatment.

Application of nanoparticles in the treatment of gliomas.

Elena Fazzari
Investigation
;
Salvatore Massimiliano Cardali
Membro del Collaboration Group
;
Maria Caffo.
Writing – Original Draft Preparation
2020

Abstract

Malignant gliomas are the most common primary brain tumors in adults up to an extent of 78% of all primary malignant brain tumors. The efficacy of current multimodal therapeutic strategies in gliomas is limited by the lack of specific therapies against malignant cells, and the prognosis in patients affected by primary brain tumors is still very unfavorable. Late diagnosis and the limitation of conventional therapies, which may result from inefficient delivery of the therapeutic or contrast agent to brain tumors are major reasons for this unsolved clinical problem. The difficult in overcoming the blood-brain barrier is the biggest obstacle for chemotherapeutics, which cannot reach the tumor bed as efficacious doses. The advent of nanotechnology could revolutionized the approach to that. Nanotechnology in biomedical research has quickly found its own niche in clinical methodologies including imaging, diagnostic, and therapeutics. Nanoparticles are versatile, thanks to their particular chemical configuration, and are able to go through the blood-brain barrier carrying drugs or genes targeted against brain tumors. Nanoparticle systems provide prolonged drug delivery directly to the tumor following direct intracerebral injection or by functionalizing the material surface with peptides and ligands allowing the drug-loaded material to be specifically target the tumor cells. In this chapter we describe the principal applications of nanomedicine in brain tumor treatment. Finally, we will report various preclinical and/or clinical studies in brain tumor treatment.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3160799
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact